Group 1: R&D and Product Development - The company has increased investment in R&D and improved its R&D team, with the Shanghai R&D center completed in August 2024, enhancing collaboration with the Harbin center [2] - In August 2024, the company launched over 10 new products utilizing supramolecular encapsulation and co-crystal technologies, receiving positive market feedback [2] - The company currently has 4 types of Class II medical devices and is developing 2 additional products, with progress on R&D meeting expectations [4] Group 2: Sales and Market Strategy - Online sales revenue reached 472 million CNY, accounting for 50.26% of total sales, while offline sales were 467 million CNY, making up 49.74% [3] - The company adopts a multi-channel sales model, integrating online and offline strategies to drive revenue growth [3] - The company will not engage in price wars, focusing instead on maintaining a mid-to-high-end market position and enhancing brand recognition [3] Group 3: Future Vision and Market Position - The company aims to strengthen brand building and market expansion, aspiring to become a leading force in the skincare industry both in China and globally [4] - The company emphasizes continuous product innovation and upgrades as a long-term growth driver [4]
敷尔佳(301371) - 2024年9月9日投资者关系活动记录表